

Review

Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics

Tomislav Čaval[✉], Frederico Alisson-Silva, Flavio Schwarz

InterVenn Biosciences, South San Francisco, California.

✉ Corresponding author: tomislav.caval@venn.bio

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <http://ivyspring.com/terms> for full terms and conditions.

Received: 2022.12.12; Accepted: 2023.04.13; Published: 2023.04.23

Abstract

Cell surface glycosylation has a variety of functions, and its dysregulation in cancer contributes to impaired signaling, metastasis and the evasion of the immune responses. Recently, a number of glycosyltransferases that lead to altered glycosylation have been linked to reduced anti-tumor immune responses: B3GNT3, which is implicated in PD-L1 glycosylation in triple negative breast cancer, FUT8, through fucosylation of B7H3, and B3GNT2, which confers cancer resistance to T cell cytotoxicity. Given the increased appreciation of the relevance of protein glycosylation, there is a critical need for the development of methods that allow for an unbiased interrogation of cell surface glycosylation status. Here we provide an overview of the broad changes in glycosylation at the surface of cancer cell and describe selected examples of receptors with aberrant glycosylation leading to functional changes, with emphasis on immune checkpoint inhibitors, growth-promoting and growth-arresting receptors. Finally, we posit that the field of glycoproteomics has matured to an extent where large-scale profiling of intact glycopeptides from the cell surface is feasible and is poised for discovery of new actionable targets against cancer.

Keywords: Cancer; Mass Spectrometry; Glycosylation; Glycoproteomics; Immune checkpoints

Introduction

Glycans are intimately involved in almost every biological process [1]. Perhaps the most striking is their role in cancer development where cellular and metabolic changes during oncogenic transformation lead to the expression of aberrant glycosylation on the cell surface. Consequently, aberrant glycosylation has been associated with the acquisition of all the cancer hallmarks [2]; such as enhancing cell proliferation through regulation of growth factor receptors, resistance to cell death through modification of cell death receptors, and escape from immune responses through alteration of the stability of ligands of immune checkpoint receptors. The study of protein glycosylation has been marred by technical challenges in the past. Recently, mass spectrometry has risen as one of the most powerful approaches to study protein glycosylation. For example, analysis of released glycans has reached a stage where high throughput, sensitivity, accuracy, and reproducibility is commonly

achieved, enabling detailed-insight into cancer glycosylation [3–5]. However, with the rising awareness of the roles of glycosylation on specific proteins and glycosylation sites there is a pressing need to reach the same level for intact glycopeptide analysis. While such an approach is potentially more informative, high entry barriers prevented widespread acceptance. Recently, through large scale community efforts great strides have been made in software development, making glycoproteomics more accessible [6–9]. Moreover, collection of sophisticated methods of glycopeptide enrichment [10,11] and fragmentation [11,12] are enabling large-scale glycoproteomic analysis of cells, tissues and bodily fluids.

In this review, we focus on the importance of the structure-function nexus for glycoproteins on the surface of cancer cells: we describe examples of broad glycosylation changes observed in cancer and highlight their function on selected proteins involved

in cancer development, progression and immune evasion. We then posit that large-scale intact glycopeptide profiling from the cell surface is well within reach, unraveling a new layer of biological information and promising new targets for development of more effective therapies. While our review predominantly focused on *N*-glycosylation, mainly due to technological maturity, it is worth pointing out that other types of glycosylation are also being increasingly explored (for a review, see [13–16]).

Broad glycosylation changes at the surface of cancer cells

Numerous studies have implicated aberrant glycosylation on cancerous cells leading to the development of their metastatic and invasive potential [17–23]. Cancer cells rewire their metabolism to promote growth, survival, proliferation, and long-term maintenance. A common feature of cancer cells is an increase in glucose uptake and its fermentation to lactate even in the presence of oxygen, a metabolic rewire known as Warburg effect that sustains the high energy demand of cancer cells [24]. The increased glycolysis influx in tumor cells is followed by increased flux through the hexosamine biosynthetic pathway (HBP), a branch of glycolysis that is initiated by the rate limiting enzyme Glutamine: Fructose-6-phosphate aminotransferase (GFAT) [25]. The HBP is responsible for the production of UDP-N-acetylglucosamine (UDP-GlcNAc), an activated monosaccharide required for *N*-glycosylation that also serves as metabolic precursors for UDP-GalNAc and CMP-Neu5Ac [26], therefore strongly impacting cell surface glycosylation during cancer [27].

Hypersialylation of cancer cells results from either altered sialyltransferase substrate availability, as mentioned above, or altered levels of sialyltransferases and neuraminidases [28]. Hypersialylation generally increases ligands for sialic acid-binding immunoglobulin type lectins (Siglecs), which are commonly expressed on the surface of immune cells [29]. Hypersialylated glycans from tumor cells can engage Siglecs expressed in dendritic cells [30], natural killer cells [31], tumor associated macrophages [32] and CD8⁺ T cells [33] promoting immunosuppressive signaling, and endowing cancer with the ability to avoid detection and removal by the immune system. Recent studies have put Siglecs on the roadmap as potential targets in cancer immunotherapy [34–37] and introduced antibody-sialidase conjugates to remove Siglec ligands and improve immune recognition [38,39]. In a proof of principle study, trastuzumab-sialidase conjugate overcome antibody dependent cell cytotoxicity (ADCC) resistance in breast cancers with low HER2 levels [38].

Besides sialylation, an increase in fucosylation is also a common feature in cancer development and progression. Fucosyltransferase 8 (Fut8), the enzyme responsible for core fucosylation, shows low expression in healthy liver and is markedly overexpressed in cancer. Recently, a matched characterization of glycosylation between primary and metastatic melanoma patient derived tissues has been described, revealing FUT8 as a driver of melanoma metastasis [40]. Mechanistically, the study demonstrated that TGFβ-Induced Factor Homeobox 2 (TGIF2) regulates FUT8 transcription which add core fucose to neural cell adhesion molecule, L1CAM, resulting in altered L1CAM activity and/or interactions with other growth factor receptors. This is likely only the tip of the iceberg of unexplored biology.

In addition to its role during TGFβ signaling, fucosyltransferases are also involved in the synthesis of the carbohydrate antigens sialyl Lewis a (sLe^a) and sialyl Lewis x (sLe^x), terminal *N*-glycan tetrasaccharide structures composed of Siaα2-3Galβ1-3(Fuca1-4)GlcNAc and Siaα2-3Galβ1,4(Fuca1-3)GlcNAc, respectively. sLe^x is constitutively expressed on the cell surface of leukocytes and is the minimum epitope required for leukocyte engagement to E-selectins expressed on endothelial cells during leukocyte rolling [41]. However, both sLe structures have been frequently observed in a number of cancers and are known to influence metastatic potential [42,43] by facilitating tumor cell interaction with selectins expressed on leukocytes, platelets and endothelium [44]. The expression of sLe^x in estrogen receptor alpha-positive breast cancers correlated with bone metastasis, and both sLe^x and sLe^a expression correlated with metastasis and poor survival in colorectal cancer [43,45,46]. These observations have proven useful in development of biomarkers for diagnosis of tumor burden (i.e. sLe^a, known as CA19-9, in pancreatic cancer). In fact, the introduction of glycosyltransferase genes leading to the expression of sLe^a antigen in mice that otherwise lack it led to pancreatitis and pancreatic cancer [47]. In this study CA19-9 modification of the matricellular protein Fibulin 3 in mice increased its interaction with EGFR resulting in hyperactivation of this signaling pathway. This work undoubtedly paves the way for using sLe^a as an actionable therapeutic target, and indicates that altered glycosylation could be causative as opposed to being merely correlative with disease.

Lastly, one intriguing epitope gaining recognition is the presence of bisecting GlcNAc on *N*-glycans, catalyzed by GlcNAc-T III enzyme encoded by *Mgat3* gene that has been reported to be immunosuppressive almost 30 years ago [48,49]. For example, bisecting GlcNAc *N*-glycans are thought to

play a key role in human sperm evading maternal immune response. In cancer, however, the dominant role of bisecting GlcNAc appears to be suppression of terminal N-glycan modifications [50].

Functional consequences of aberrant glycosylation at a protein level

While changes of the cell surface glycosylation in cancer are well described, less is known about whether such changes are simply correlative of cancer or are causative in neoplasia. Similarly, little is known about functional pathways that may be controlled by aberrant glycosylation. In this section, we focus on selected examples where aberrant N-glycosylation directly influences the underlying protein, and consequently downstream signaling pathways in cancer. While literature is riddled with examples of glycosylation influencing protein function in cancer, and we point the readers to a comprehensive recent review [51], it can broadly be ascribed to glycosylation changes on growth-promoting and/or growth-arresting cell surface receptors. A landmark study demonstrated that N-glycan multiplicity, which means the number of N-glycosites on a given protein backbone, is in general higher for growth-promoting receptors and lower on growth-arresting receptors [52]. The N-glycan multiplicity serves as a sensor of intracellular glucose metabolism and can be regulated

to either reduce cell growth by lowering the cell surface levels of N-glycans or to increase cell growth via increasing N-glycan amount [52,53]. In the next part we briefly cover recent examples of specific glycans influencing function of cell surface proteins.

Epidermal growth factor receptor (EGFR), a receptor tyrosine kinase with 12 potential N-glycosylation sites, is perhaps the most famous example of functional influence of glycosylation on a cell surface protein [54]. While EGFR core fucosylation promotes receptor dimerization [55], the presence of the antennary α 1-3 (sLe^x) fucose or increased EGFR sialylation have been shown to attenuate EGFR dimerization and signaling [56]. Additionally, the ST6GAL1 catalyzed α 2-6 sialylation of EGFR was shown to confer resistance to gefitinib, an EGFR inhibitor [57]. Intriguingly, a simple switch of antennary fucose from α 1-3 (sLe^x) to α 1-4 (sLe^a) seems to be associated with hyperactivation of EGFR in gastric cancer, and can be therapeutically targeted with anti-sLe^a antibody [58]. Recently, presence of bisecting-GlcNAc was shown to also attenuate EGFR signaling and decrease migratory and proliferative potential of breast cancer cells [59]. Finally, in addition to forming homodimers to enable downstream signaling, EGFR is also known to form heterodimers and there are preliminary reports demonstrating that specific glycan-glycan interactions




Figure 1. Aberrant glycosylation in cancer. **A**) Overview of general N-glycosylation changes described in cancer. Specific examples of functional consequences of aberrant N-glycosylation are depicted for the B7 family of immune checkpoints and Endothelial Growth Factor Receptor (EGFR) in panels **B** and **C**, respectively. Figure created with BioRender.com.

can drive their formation [60]. In fact, recent work has implicated α 2,6-sialylated N-glycans of a known dimerization partner of EGFR, human epidermal growth factor receptor 2 (ErbB2/HER2), as a driver of trastuzumab resistance in gastric cancer [61,62]. Mechanistically a removal of α 2,6-sialylated N-glycans from ErbB2 via silencing of sialyltransferase ST6GAL1 leads to increase of α 2,3-sialylation, and terminal fucosylation, resulting in stabilization of ErbB2 dimers at the cell surface rendering them more sensitive to trastuzumab induced cytotoxicity. The authors of this study also discuss the possibility of glycosylation decreasing ErbB2's ability to form heterodimers with EGFR and downregulating EGFR activation following trastuzumab treatment [62].

Vascular endothelial growth factor receptor-2 (VEGFR2), another receptor tyrosine kinase with 18 potential N-glycosylation sites, regulates the relationship between tumor cells and endothelium. VEGFR signaling is upregulated by tumor hypoxia promoting angiogenesis aiding the tumor cells into and out of the blood stream [63,64]. Moreover, it is also known that hypoxic microenvironments can increase N-glycans branching of VEGFR2 and that this glycan remodeling makes tumor vasculature resistant to anti-VEGF treatment. This hypoxia-promoted increase in VEGFR2 N-glycan branching leads to a stronger interaction between Galectin 1 and endothelial cells, resulting in VEGFR2 activation in a ligand-independent manner. In addition, a follow up study demonstrated that the capping of N-glycans at Asn-247 of VEGFR2 by sialic acid, tunes ligand-dependent activation and signaling of VEGFR2 in endothelial cells [65]. By using in-depth glycomics, glycoproteomics, and functional profiling, the authors revealed that the capping of the Asn-247 N-glycan with sialic acid impairs receptor function while the absence of sialic acid units leads to its activation [65]. This is very similar to the observations described in previous paragraph on the role of glycans in EGFR signaling except for fucosylation, which appears not to play a role in VEGFR2 activation. In the case of growth-arresting receptor, it is noteworthy how core fucosylation of the Transforming growth factor beta receptor 1 (TGF β R1) is required for its function. Here, FUT8 catalyzed addition of fucose in α -1,6-linkage to core N-acetylglucosamine of N-glycans remodels TGF β receptor fucosylation and promotes EMT in breast cancer cells [66]. Similarly, the TGF β R antennary fucosylation mediated by FUT3 and FUT6 also promotes EMT in human colorectal cancer cells [67]. Lastly, intraperitoneal injection of exogenous TGF- β 1 in *FUT8 null* mice rescued the emphysema-like phenotype displayed in the lung of these mice [68], representing one of the first examples

of glycoprotein specific rescue in a glycosylation deficient animal model. Next, the presence of bisecting GlcNAc was shown to inhibit TGF- β 1 induced epithelial to mesenchymal transition (EMT) [69], again likely due to N-glycan bisection inhibiting poly-N-Acetylglucosamine (polyLacNAc) elongation and interaction with galectin-3, which stabilizes surface expression TGF β R [70,71].

Finally, one class of interesting molecules where glycosylation is shown to play crucial role are the members of Immunoglobulin-like immunosuppressive molecules, also known as checkpoint inhibitors, such as programmed death ligand 1 and 2 (PD-L1, PD-L2) and cytotoxic T-lymphocyte associated protein 4 (CTLA4) [72]. A monoclonal blocking antibody targeting the glycosylated form PD-L1 in breast cancer cells blocked PD-L1/PD-1 interaction by promoting PD-L1 internalization and degradation [72] therefore inducing a potent tumor cell killing effect. The glycosylation of PDL-1 in the triple negative breast cancer cells was shown to be induced by EGFR signaling-mediated upregulation of β -1,3-N-acetylglucosaminyl transferase (B3GNT3), an enzyme catalyzing the addition of polyLacNAc repeats to PDL-1. The presence of polyLacNAc on PD-L1 physically stabilizes its interaction with PD-1 causing suppression of T-cell activity. Finally, the authors also utilized this glycosylation signature to develop an antibody drug conjugate specifically binding to polyLacNAc containing PD-L1 that was validated in a syngeneic mouse model of human breast cancer [66]. Multiple follow up studies have since exploited the role of PD-L1 glycosylation as a therapeutic target [73–75].

Interestingly, another member of the B7 homolog family [76], PD-L1 and PD-L2 are also known as B7-H1 and B7-DC, respectively, B7-H4 molecule was shown to be stabilized by glycosylation in triple negative breast cancer. Specifically, upregulation of STT3A, an oligosaccharyltransferase required for N-glycan transfer to the protein backbone, leads to a higher N-glycosylation site occupancy of B7-H4 preventing ubiquitination and subsequent degradation [77]. Coincidentally, B7-H3 was shown to be stabilized by core fucosylation and the combination of fucosyltransferase inhibitor, 2F-Fuc, with anti-PDL1 resulted in enhanced therapeutic efficacy in B7-H3 positive triple negative breast cancer [78]. This begs the question if glycosylation could be one of the uniting factors behind the B7 family in cancer?

Beyond the B7 family, a landmark work has provided a clue to a 40-year-old mystery on why cell surface desialylation of T-cells leads to an increase in T cell activation [79]. Sialylated glycans either on T

cells or antigen presenting cells can act as alternative ligands for CD28 competing with CD80(B7-1) binding therefore attenuating co-stimulation. Additionally, since CD28-CD80 axis is one of key pathways to reviving exhausted T cells in immune checkpoint therapy, targeted desialylation could emerge as a powerful way forward in enhancing CD8+ T cell anticancer immune responses [80,81].

Glycosylation influence over the immune system is far beyond these selected few examples. For example, a recent CRISPR activation screening has identified B3GNT2, another enzyme involved in polyLacNAc elongation, as a key driver of tumor cell resistance to T cell cytotoxicity [82]. In this elegant study, the authors show that the presence of polyLacNAc on around a dozen of cancer cell surface ligands drives resistance against T cell mediated cytotoxicity across several different cancers. However, this is likely only scratching the surface of all the possible ligands carrying polyLacNAc elongation, a modification that is analytically challenging to identify and position when dealing with thousands of different proteins at once. Altogether, these examples clearly show how the changes in cellular glycosylation can confer plasticity and modulate cell differentiation processes and immune response during cancer. The development of methods to perform in-depth characterization of cell surface glycoproteins, and position the glycosylation to specific sites of the proteins would greatly contribute to understanding the function of the diverse world of glycosylation changes that occur during disease.

Coming of age of intact cell surface glycopeptide profiling

The isolated examples described above of the role that glycosylation plays in modulating receptors' properties highlight the pressing need of determining the fine picture of the cell surface. What else is hiding on the cell surface? What kind of biology, mechanistic insights and therapeutic targets could we uncover by large scale cell surface glycoproteomics? Even more so, are there any unexpected structures like the recently discovered glycoRNAs that have been hiding in plain sight [83]? In this part, we first provide a brief overview of mass spectrometry based glycoproteomics. Next, we summarize the workflows developed for analysis of formerly glycosylated peptides — glycopeptides that have been enzymatically deglycosylated prior to analysis — from cell surfaces, and present select few examples of intact glycopeptide mapping that provide rich information on the diversity of glycosylation of cell surface glycoproteins.

Large scale glycoproteomic analysis

Considering a recent deluge of reviews covering all aspects of glycoproteomics [11], we instead provide a succinct overview of glycopeptide analysis evolution and point the readers toward recent focused reviews on glycopeptide enrichment [10], fragmentation [12] and data analysis [84,85].

Originally, one of the biggest challenges in intact glycopeptide analysis is the reliance on workflows originally developed for the analysis of tryptic peptides, mainly stemming from the fact that most MS instruments were built and optimized around the analysis of peptides, as opposed to glycopeptides. So, it comes as no surprise that early large-scale efforts were focused on mapping deglycosylated (PNGase F treated) *N*-glycoproteins.

In 2003 a seminal publication by Zhang et al. based on the *N*-glycoprotein oxidation and subsequent immobilization via hydrazide chemistry enabled large scale quantitative mapping of formerly *N*-linked glycopeptides providing valuable insight into glycoprotein landscape of human serum [86]. Similar workflows, covered below have also become one of the key approaches for cell surface (glyco)proteome mapping. Following study by Zielinska et al. repurposed filter-aided-sample preparation (FASP) by including lectin enrichment for isolation of *N*-glycopeptides and subsequent mapping of over 6000 formerly *N*-glycosylated peptides, gaining insight into the topological constraints of *N*-glycosylation [87]. On the other hand, the large-scale identification of intact glycopeptides was lagging, mainly because characterization of glycopeptides with collision-induced dissociation (CID) was technically challenging, and data analysis relied on a large degree of manual interpretation. Alternative fragmentation strategies such as higher energy collisional dissociation (HCD), electron-based fragmentation methods (ECD, ETD) and their combination into so called hybrid fragmentation approaches such as electron-transfer/higher-energy collision dissociation, have proven invaluable for characterization of intact glycopeptides [88–95], yielding rich fragmentation spectra that could be exploited to build better software solutions for data analysis. Indeed, over the last few years we have witnessed a small revolution in the development of numerous search engines tailored to identification and quantitation of intact glycopeptides [96–100], and we now witness studies characterizing over ten thousand on intact glycopeptides [101,102].

Finally, what is widely known, but often not stressed enough is that glycoproteomic approaches only provide a mass of a glycan attached to the peptide backbone. Actual glycan structure is often

inferred based on the glycan biosynthetic pathway, and the vast body of literature knowledge stemming from the structural analysis of the released glycans serves as a reference when searching glycopeptide data [103–106]. Ideally, a perfect glycoproteomic experiment would also involve parallel characterization of the glycome and *N*-glycosite containing peptides [107], a term recently popularized as glycomics-assisted glycoproteomics [108]. Additionally, it is worthwhile mentioning continuous advances in chemoenzymatic synthesis of glycans and glycoproteins, enabling access to libraries of structurally defined standards [109–114]. Such standards have the potential to propel glycoproteomics forward through systematic investigation of fragmentation pattern of well-defined isomeric/isobaric glycan structures [115–117], akin to how libraries of synthetic peptides have advanced proteomics [118].

Cell surface; from proteomics to glycoproteomics

Over a decade ago, oxidation and biocytin hydrazide labeling of cell surface glycans allowed the identification of formerly glycosylated peptides [119]. This relatively simple but powerful method later enabled the definition of a cell surface glycoprotein atlas covering over 70 mouse and human cell lines [120]. A key effort leading to the widespread use of cell surface capture (CSC) methodology is the parallel development of software tools for exploration and validation of CSC data. Notable examples here include SURFY, a machine learning-based approach for *in silico* exploration of the human surfaceome [121], and its extensive developments, providing end-to-end solution from sample preparation, data analysis, validation and visualization of CSC experiments through the modular CellSurfer platform [122–124]. However, the downside of the original CSC technology is the reliance on enzymatic deglycosylation of labeled glycopeptides with PNGase F, which leads to the loss of information on underlying glycans. This issue was resolved by optimizing the sodium periodate oxidation conditions to selectively modify sialic acids on the cell surface, followed by hydrazide labeling and subsequent release of the captured glycopeptides via sialic acid cleavage in mild acid conditions. Although this approach preserved most of the glycans, it resulted in limited coverage of cell surface glycoproteome [125]. In addition to CSC technology, the exploitation of unique chemistries has allowed the development of a variety of glycoprotein capture techniques. Briefly, early work by Werner Reutter group reported that feeding the cells with *N*-acyl derivatives of *N*-acetylmannosamine, a

metabolic precursor of sialic acid, can be used to modulate *N*-acyl groups of sialic acids [126]. Bertozzi group built on this research and developed a toolkit of unnaturally modified sugar analogues with azide functional groups, which get biosynthetically incorporated into glycans with the azide serving as a labelling target via copper (I)-catalyzed azide-alkyne cycloaddition, a reaction termed click chemistry for which Barry Sharpless and Morten Meldal were awarded Nobel prize in chemistry in 2022 [127,128]. Carolyn Bertozzi then further built on this research by circumventing the toxicity of copper catalyst inventing strain-promoted azide-alkyne cycloaddition, which made these reactions compatible with living cells and animals, now known as bioorthogonal chemistry, for which she was also awarded Nobel prize in chemistry in 2022 [129–132].

Alternatively, beyond metabolic labeling, researchers have exploited the promiscuity of ST6 beta-galactoside alpha-2,6-sialyltransferase 1 (ST6Gal-I) for sugar donor substrate utilizing biotinylated CMP-activated sialic acid for enzymatic biotin-labeling of cell surface glycoproteins [133]. Furthermore, a number of powerful approaches building on the foundational pioneering Bertozzi/Meldal/Sharpless work have been developed and used to profile cell surface sialoglycoproteins [134], allowing analysis of changes upon drug treatment or bacterial infection [135,136]. Promisingly, recent combinations of metabolic labeling and isotopic recoding have provided a blueprint for detection of glycopeptides in complex mixtures, as well as paved a way forward for large-scale quantitative exploration of the glycoproteome [137–139].

The promise of cell surface glycoprotein analysis through CSC profiling is beautifully illustrated by a large-scale comparative analysis of the regulation driven by oncogenes [140]. Expression of six different oncogenes, namely EGFR, HER2, KRAS, BRAF, MEK, AKT, in isogenic epithelial cell lines demonstrated both the uniqueness in dysregulated glycoproteins and the commonalities in general biological processes such as nutrient transport, adhesion and various tumor suppressing immune modulators. Interestingly, remodeling of each oncogene could be reverted to a more common state by addition of MEK inhibitor.

Recent advances in microscale application of CSC, have reported identification of 276 [141] and 800 [142] glycoproteins starting from 1 million myeloma B cells, enabling the study of primary cancer cells for discovery of potential immunotherapeutic targets [142]. Briefly, microscale CSC developed by Ferguson et al. enabled cell surface profiling of myeloma plasma cells leading to identification of CCR10 as a target for chimeric antigen receptor T cells and

identified a panel of glycoprotein biomarkers of resistance to lenalidomide and bortezomib therapy [142]. However, the current CSC technology is currently not permissive to intact glycopeptide profiling, which has the potential to uncover a whole new layer of biology as well as to identify better biomarkers and drug targets.

Beyond CSC, approaches based on differential solubility and ultracentrifugation have yielded success in characterization of intact glycopeptides from the cell surface [143–145]. Park et al. study specifically evaluated the incorporation of unnatural sialic acid variants through metabolic labeling of cells with N-azidoacetyl-mannosamine (Ac4ManNAz) from plasma membrane fractions identifying over 2000 unique glycoforms in Caco-2 (Adenocarcinoma) cell line [143]. Another study demonstrated impressive sensitivity, mapping thousands of glycopeptides from a limited amount of starting material, representing an opportunity for in-depth investigation of membrane glycoproteome of clinically relevant samples [145]. Similarly, a sensitive stepwise glycopeptide enrichment approach based on zwitterionic hydrophilic interaction chromatography has been developed [146]. The optimized protocol was used on non-small cell lung cancer identifying over 7000 intact glycopeptides from crude membrane

fraction covering some of most biologically important cell surface glycoproteins such as MET, ERBB2, ERBB3, PD1L1, IGF1R, AXL, and EGFR. Notwithstanding just the receptor activation, the insights into the glycosylation of these receptors was exhaustive. For example, just in the EGFR case the authors were able to characterize 10 of 12 N-glycosylation sites of EGFR spanning over 150 unique intact glycopeptides paving the way for future comparative studies on the role of aberrant glycosylation at the cell surface.

Next to general exploration of cell surface glycosylation, recent recognition of glycan binding proteins, such as Siglecs and Galectins, in regulation of immune system and their potential as novel immune checkpoint inhibitors has resulted in development of approaches for targeted identification of glycan binding proteins on the cell surface [147–152]. Although historically considered to bind, almost indiscriminately, sialic acid on the cell surfaces, recent data point to unique ligands of siglecs such as CD43 for Siglec-7, and strikingly glycosylated RNAs expressed on the cell surfaces recognized by Siglecs 11, and 14 [153,154]. Along the same lines, Galectins also appear to have discriminate ligands, such as interaction of Galectin-9 with glycan at site N166 of PD-1 leading to lattice formation of Gal-9/PD-1/




Figure 2. Overview of approaches for cell surface (Glyco)proteomics. (Created with BioRender.com).

TIM-3 and inhibits Galectin-9 induced T-cell apoptosis [155]. Recent technological developments by Lebrilla group in systematic probing of cell surface sialic-acid mediated protein by crosslinking mass spectrometry, and Huang group in proximity labeling of Galectin-3 ligands represents a promising way forward for capturing fine specificities of glycan binding proteins in living cells [150,151].

Conclusion

The concerted community efforts on improving many aspects of the glycoproteomic workflow, from sample preparation to instrumentation sensitivity, fragmentation approaches and user-friendly data analysis software have enabled significant advancements in the field of glycoproteomics [156]. As a result, we are starting to observe a rise in large scale glycoproteomics analysis of primary tissue samples. For example, glycoproteomic mapping of 119 high-grade serous ovarian carcinoma tissue samples has revealed its power in tumor molecular subtyping [156]. Identification of aberrant glycosylation in cancer cells can be exploited for the development of tumor-targeting drugs [72,157] giving further support for the need to develop large scale cell surface glycoproteomics approaches. Indeed, powerful approaches have been deployed to target solid malignancies by either developing chimeric antigen receptor T (CAR T) cells that recognize aberrant cancer surface glycosylation or by removing N-glycosylation to unmask the hidden CAR T cell targets [158-160], underscoring the crucial importance of evaluating the status of glycosylation in patient derived samples [161]. Additionally, glycoproteomics can be applied towards the characterization of the immune cells that combat cancer, to relate glycosylation patterns that may affect binding of ligands or signaling pathways to distinct activation or suppression states. Glycoproteomics can also assist in the design of drugs that specifically target distinct glycoforms of receptors in immune cells, potentially leading to more effective therapeutics with fewer side effects [162,163].

Cell surface glycoproteomics can also find application in the discovery of new biomarkers for disease diagnosis and prediction of drug response. For example, while glycoproteomics of liquid biopsies provides a significant advantage compared to next generation sequencing approaches as it allows detection of earlier stages of disease [164], glycoproteomics of circulating cells and exosomes in blood may provide additional biomarkers [165]. Similarly, while techniques like RNA sequencing have brought a wealth of knowledge about the cell types that populate the tumor microenvironment, high

resolution glycoproteomics of tumor biopsies may unlock an additional layer of information that can be related to the physiological state of the cells found in the tumor microenvironment [166].

The knowledge enabled by the accurate detection of the dynamic glycan structural changes combined with peptide sequence, compared to peptide or glycan measurements alone, has enormous potential across many fields of biology and medicine. By defining the complex and diverse glycosylation patterns of surface receptors, cell surface glycoproteomics will drive significant advances in our understanding of disease pathology. We have just scratched the surface of known glycosylation and new opportunities for target identification and biomarker discovery await to be scooped from the cancer cell surface.

Competing Interests

The authors are employees of InterVenn Biosciences.

References

1. Varki A. Biological roles of glycans. *Glycobiology*. 2017; 27: 3–49. Available at:
2. Munkley J, Elliott DJ, Munkley J, Elliott DJ. Hallmarks of glycosylation in cancer. *Oncotarget*. 2016; 7: 35478–89.
3. Sethi MK, Kim H, Park CK, et al. In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation. *Glycobiology*. 2015; 25: 1064–78.
4. Kailemia MJ, Xu G, Wong M, et al. Recent Advances in the Mass Spectrometry Methods for Glycomics and Cancer. *Anal Chem*. 2018; 90: 208–24.
5. Trbojević-Akmačić I, Lageveen-Kammeijer GSM, Heijs B, et al. High-Throughput Glycomic Methods. *Chem Rev*. 2022; 122: 15865–913.
6. Polasky DA, Yu F, Teo GC, Nesvizhskii AI. Fast and comprehensive N- and O-glycoproteomics analysis with MSFragger-Glyco. *Nat Methods*. 2020 17:11; 17: 1125–32.
7. Shen J, Jia L, Dang L, et al. StrucGP: de novo structural sequencing of site-specific N-glycan on glycoproteins using a modularization strategy. *Nat Methods*. 2021 18:8. 2021; 18: 921–9.
8. Cao W, Liu M, Kong S, Wu M, Zhang Y, Yang P. Recent Advances in Software Tools for More Generic and Precise Intact Glycopeptide Analysis. *Mol Cell Proteomics*. 2021; 20: 100060.
9. Kawahara R, Chernykh A, Alagesan K, et al. Community evaluation of glycoproteomics informatics solutions reveals high-performance search strategies for serum glycopeptide analysis. *Nat Methods*. 2021 18:11. 2021; 18: 1304–16.
10. Riley NM, Bertozzi CR, Pitteri SJ. A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry–Based Glycoproteomics. *Mol Cell Proteomics*. 2021; 20: 100029
11. Bagdonaite I, Malaker SA, Polasky DA, et al. Glycoproteomics. *Nat Rev Methods Primers*. 2022; 2.
12. Reiding KR, Bondt A, Franc V, Heck AJR. The benefits of hybrid fragmentation methods for glycoproteomics. *Trends Analyt Chem*. 2018; 108: 260–8.
13. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. *Nat Rev Cancer*. 2015; 15: 540–55.
14. Kudelka MR, Ju T, Heimburg-Molinaro J, Cummings RD. Simple sugars to complex disease—mucin-type O-glycans in cancer. *Adv Cancer Res*. 2015; 126: 53–135.
15. Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. *Biochim Biophys Acta Rev Cancer*. 2021; 1875: 188464.
16. Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. *Nat Rev Mol Cell Biol* 2020 21:12. 2020; 21: 729–49.
17. Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. *Nat Med*. 2000; 6: 306–12.
18. Wei T, Liu Q, He F, et al. The role of N-acetylglucosaminyltransferases V in the malignancy of human hepatocellular carcinoma. *Exp Mol Pathol*. 2012; 93: 8–17.

19. Häuselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. *Front Oncol.* 2014; 4:28.
20. Keeley TS, Yang S, Lau E. The Diverse Contributions of Fucose Linkages in Cancer. *Cancers.* 2019; 11: 1241.
21. Schultz MJ, Swindall AF, Bellis SL. Regulation of the metastatic cell phenotype by sialylated glycans. *Cancer Metastasis Rev.* 2012; 31: 501–18.
22. Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. *Br J Cancer.* 2021; 124: 76–90.
23. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. *Nat Rev Cancer.* 2015; 15: 540–55.
24. Warburg O. The Metabolism of Carcinoma Cells. *J Cancer Res.* 1925; 9: 148–63.
25. Oliveira IA, Allonso D, Fernandes TVA, et al. Enzymatic and structural properties of human glutamine:fructose-6-phosphate amidotransferase 2 (hGFAT2). *J Biol Chem.* 2021; 296.
26. Almaraz RT, Tian Y, Bhattacharya R, et al. Metabolic flux increases glycoprotein sialylation: Implications for cell adhesion and cancer metastasis. *Mol Cell Prot.* 2012; 11: M112.017558-1.
27. Vasconcelos-dos-Santos A, Oliveira IA, Lucena MC, et al. Biosynthetic machinery involved in aberrant glycosylation: Promising targets for developing of drugs against cancer. *Front Oncol.* 2015; 5: 138.
28. Rodrigues E, Macauley MS. Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities. *Cancers.* 2018; 10: 207.
29. Schwarz F, Fong JJ, Varki A. Human-specific evolutionary changes in the biology of siglecs. *Adv Exp Med Biol.* 2015; 842: 1–16.
30. Wang J, Manni M, Bärenwaldt A, et al. Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer. *Front Cell Dev Biol.* 2022; 10: 206.
31. Jandus C, Boligan KF, Chijioko O, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. *J Clin Invest.* 2014; 124: 1810–20.
32. Stanczak MA, Rodrigues Mantuano N, Kirchnerhammer N, et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. *Sci Transl Med.* 2022; 14: eabj1270.
33. Stanczak MA, Siddiqui SS, Trefny MP, et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. *J Clin Invest.* 2018; 128: 4912–23.
34. Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. *Nat Chem Biol.* 2013; 10: 69–75.
35. Bärenwaldt A, Läubli H. The sialoglycan-Siglec glyco-immune checkpoint – a target for improving innate and adaptive anti-cancer immunity. *Expert Opin Ther Targets.* 2019; 23: 839–53.
36. Jandus C, Boligan KF, Chijioko O, et al. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. *J Clin Invest.* 2014; 124: 1810–20.
37. Läubli H, Pearce OMT, Schwarz F, et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. *Proc Natl Acad Sci USA.* 2014; 111: 14211–6.
38. Xiao H, Woods EC, Vukojicic P, Bertozzi CR. Precision glycocalyx editing as a strategy for cancer immunotherapy. *Proc Natl Acad Sci USA.* 2016; 113: 10304–9.
39. Gray MA, Stanczak MA, Mantuano NR, et al. Targeted glycan degradation potentiates the anticancer immune response *in vivo*. *Nat Chem Biol.* 2020; 16: 1376–84.
40. Agrawal P, Fontanals-Cirera B, Sokolova E, et al. A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis. *Cancer Cell.* 2017; 31: 804–819.e7.
41. McEver RP. Selectins: initiators of leucocyte adhesion and signaling at the vascular wall. *Cardiovasc Res.* 2015; 107: 331–9.
42. Brown JR, Fuster MM, Li R, Varki N, Glass CA, Esko JD. A disaccharide-based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. *Clin Cancer Res.* 2006; 12: 2894–901.
43. Trinchera M, Aronica A, Dall'Olio F. Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers. *Biology.* 2017; 6: 16.
44. Läubli H, Borsig L. Selectins promote tumor metastasis. *Semin Cancer Biol.* 2010; 20: 169–77.
45. Shiozaki K, Yamaguchi K, Takahashi K, Moriya S, Miyagi T. Regulation of sialyl lewis antigen expression in colon cancer cells by sialidase NEU4. *J Biol Chem.* 2011; 286: 21052–61.
46. Blanas A, Sahasrabudhe NM, Rodríguez E, van Kooyk Y, van Vliet SJ. Fucosylated antigens in cancer: An alliance toward tumor progression, metastasis, and resistance to chemotherapy. *Front Oncol.* 2018; 8: 39.
47. Engle DD, Tiriac H, Rivera KD, et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. *Science.* 2019; 364: 1156–62.
48. Yoshimura M, Ihara Y, Taniguchi N. Changes of β -1,4-N-acetylglucosaminyltransferase III (GnT-III) in patients with leukaemia. *Glycoconj J.* 1995; 12: 234–40.
49. Yoshimura M, Ihara Y, Ohnishi A, et al. Bisecting N-Acetylglucosamine on K562 Cells Suppresses Natural Killer Cytotoxicity and Promotes Spleen Colonization. *Cancer Res.* 1996; 56: 412–8.
50. Nakano M, Mishra SK, Tokoro Y, et al. Bisecting GlcNAc Is a General Suppressor of Terminal Modification of N-glycan. *Mol Cell Prot.* 2019; 18: 2044–57.
51. Ferreira IG, Pucci M, Venturi G, Malagolini N, Chiricolo M, Dall'Olio F. Glycosylation as a Main Regulator of Growth and Death Factor Receptors Signaling. *Int J Mol Sci.* 2018; 19: 580.
52. Lau KS, Partridge EA, Grigorian A, et al. Complex N-Glycan Number and Degree of Branching Cooperate to Regulate Cell Proliferation and Differentiation. *Cell.* 2007; 129: 123–34.
53. Taniguchi N. A sugar-coated switch for cellular growth and arrest. *Nat Chem Biol.* 2007; 3: 307–9.
54. Takahashi M, Hasegawa Y, Gao C, Kuroki Y, Taniguchi N. N-glycans of growth factor receptors: their role in receptor function and disease implications. *Clin Sci (Lond).* 2016; 130: 1781–92.
55. Fernandes H, Cohen S, Bishayee S. Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells. *J Biol Chem.* 2001; 276: 5375–83.
56. Liu YC, Yen HY, Chen CY, et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. *Proc Natl Acad Sci USA.* 2011; 108: 11332–7.
57. Britain CM, Holdbrooks AT, Anderson JC, Willey CD, Bellis SL. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death. *J Ovarian Res.* 2018; 11.
58. Duarte HO, Balmaña M, Mereiter S, Osório H, Gomes J, Reis CA. Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor. *Int J Mol Sci.* 2018; 18.
59. Cheng L, Cao L, Wu Y, et al. Bisecting N-Acetylglucosamine on EGFR Inhibits Malignant Phenotype of Breast Cancer via Down-Regulation of EGFR/Erk Signaling. *Front Oncol.* 2020; 10.
60. Motamedi Z, Rajabi-Maham H, Azimzadeh Irani M. Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation - molecular dynamics study. *J Mol Model.* 2021; 27.
61. Duarte HO, Balmaña M, Mereiter S, Osório H, Gomes J, Reis CA. Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor. *Int J Mol Sci.* 2017; 18: 2262.
62. Duarte HO, Rodrigues JG, Gomes C, et al. ST6Gal1 targets the ectodomain of ErbB2 in a site-specific manner and regulates gastric cancer cell sensitivity to trastuzumab. *Oncogen.* 2021; 40: 3719–33.
63. Chandler KB, Costello CE, Rahimi N. Glycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis. *Cells.* 2019; 8.
64. Cheng WK, Oon CE. How glycosylation aids tumor angiogenesis: An updated review. *Biomed Pharmacother.* 2018; 103: 1246–52.
65. Chandler KB, Leon DR, Kuang J, Meyer RD, Rahimi N, Costello CE. N-Glycosylation regulates ligand-dependent activation and signaling of vascular endothelial growth factor receptor 2 (VEGFR2). *J Biol Chem.* 2019; 294: 13117–30.
66. Tu CF, Wu MY, Lin YC, Kannagi R, Yang RB. FUT8 promotes breast cancer cell invasiveness by remodeling TGF- β receptor core fucosylation. *Breast Cancer Res.* 2017; 19.
67. Hirakawa M, Takimoto R, Tamura F, et al. Fucosylated TGF- β receptors transduce a signal for epithelial-mesenchymal transition in colorectal cancer cells. *Br J Cancer.* 2014; 110: 156–63.
68. Schachter H. The search for glycan function: fucosylation of the TGF-beta1 receptor is required for receptor activation. *Proc Natl Acad Sci USA.* 2005; 102: 15721–2.
69. Takahashi M, Hasegawa Y, Gao C, Kuroki Y, Taniguchi N. N-glycans of growth factor receptors: their role in receptor function and disease implications. *Clin Sci (Lond).* 2016; 130: 1781–92.
70. Partridge EA, le Roy C, di Guglielmo GM, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. *Science.* 2004; 306: 120–4.
71. Zhang J, ten Dijke P, Wuhler M, Zhang T. Role of glycosylation in TGF- β signaling and epithelial-to-mesenchymal transition in cancer. *Protein Cell.* 2021; 12: 89–106.
72. Li CW, Lim SO, Chung EM, et al. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. *Cancer Cell.* 2018; 33: 187–201.e10.
73. Shao B, Li C-W, Lim S-O, et al. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. *Am J Cancer Res.* 2018; 8: 1837.
74. Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 Expression in Cancer. *Mol Cell.* 2019; 76: 359–70.
75. Kim B, Sun R, Oh W, Kim AMJ, Schwarz JR, Lim SO. Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation. *Mol Carcinog.* 2020; 59: 691–700.
76. West SM, Deng XA. Considering B7-CD28 as a family through sequence and structure. *Exp Biol Med.* 2019; 244: 1577.
77. Song X, Zhou Z, Li H, et al. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers. *Cancer Discov.* 2020; 10: 1872–94.
78. Huang Y, Zhang HL, Li ZL, et al. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. *Nat Commun.* 2021; 12.
79. Edgar LJ, Thompson AJ, Vartabedian VF, et al. Sialic Acid Ligands of CD28 Suppress Costimulation of T Cells. *ACS Cent Sci.* 2021; 7: 1508–15.

80. Gray MA, Stanczak MA, Mantuano NR, et al. Targeted glycan degradation potentiates the anticancer immune response *in vivo*. *Nat Chem Biol*. 2020; 16: 1376–84.
81. Skokos D, Waite JC, Haber L, et al. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. *Sci Transl Med*. 2020; 12.
82. Joung J, Kirchgatterer PC, Singh A, et al. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. *Nat Commun*. 2022; 13.
83. Flynn RA, Pedram K, Malaker SA, et al. Small RNAs are modified with N-glycans and displayed on the surface of living cells. *Cell*. 2021; 184: 3109–3124.e22.
84. Cao W, Liu M, Kong S, Wu M, Zhang Y, Yang P. Recent Advances in Software Tools for More Generic and Precise Intact Glycopeptide Analysis. *Mol Cell Prot*. 2021; 20: 100060.
85. Polasky DA, Nesvizhskii AI. Recent advances in computational algorithms and software for large-scale glycoproteomics. *Curr Opin Chem Biol*. 2023; 72: 102238.
86. Zhang H, Li X, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. *Nat Biotechnol*. 2003; 21: 660–6.
87. Zielinska DF, Gnad F, Wiśniewski JR, Mann M. Precision mapping of an *in vivo* N-glycoproteome reveals rigid topological and sequence constraints. *Cell*. 2010; 141: 897–907.
88. Singh C, Zampronio CG, Creese AJ, Cooper HJ. Higher energy collision dissociation (HCD) product ion-triggered electron transfer dissociation (ETD) mass spectrometry for the analysis of N-linked glycoproteins. *J Proteome Res*. 2012; 11: 4517–25.
89. Cao L, Tolić N, Qu Y, et al. Characterization of intact N- and O-linked glycopeptides using higher energy collisional dissociation. *Anal Biochem*. 2014; 452: 96–102.
90. Wu SW, Pu TH, Viner R, Khoo KH. Novel LC-MS2 product dependent parallel data acquisition function and data analysis workflow for sequencing and identification of intact glycopeptides. *Anal Chem*. 2014; 86: 5478–86.
91. Yu Q, Wang B, Chen Z, et al. Electron-Transfer/Higher-Energy Collision Dissociation (ETHCD)-Enabled Intact Glycopeptide/Glycoproteome Characterization. *J Am Soc Mass Spectrom*. 2017; 28: 1751–64.
92. Yang H, Yang C, Sun T. Characterization of glycopeptides using a stepped higher-energy C-trap dissociation approach on a hybrid quadrupole orbitrap. *Rapid Commun Mass Spectrom*. 2018; 32: 1353–62.
93. Čaval T, Zhu J, Heck AJR. Simply Extending the Mass Range in Electron Transfer Higher Energy Collisional Dissociation Increases Confidence in N-Glycopeptide Identification. *Anal Chem*. 2019; 91: 10401–6.
94. Riley NM, Hebert AS, Westphall MS, Coon JJ. Capturing site-specific heterogeneity with large-scale N-glycoproteome analysis. *Nature Commun*. 2019; 10: 1–13.
95. Riley NM, Malaker SA, Driessen MD, Bertozzi CR. Optimal Dissociation Methods Differ for N- and O-Glycopeptides. *J Proteome Res*. 2020; 19: 3286–301.
96. Polasky DA, Yu F, Teo GC, Nesvizhskii AI. Fast and comprehensive N- and O-glycoproteomics analysis with MSFragger-Glyco. *Nat Methods*. 2020; 17: 1125–32.
97. Shen J, Jia L, Dang L, et al. StrucGP: de novo structural sequencing of site-specific N-glycan on glycoproteins using a modularization strategy. *Nat Methods*. 2021; 18: 921–9.
98. Zeng WF, Cao WQ, Liu MQ, He SM, Yang PY. Precise, fast and comprehensive analysis of intact glycopeptides and modified glycans with pGlyco3. *Nat Methods*. 2021; 18: 1515–23.
99. Fang Z, Qin H, Mao J, et al. Glyco-Decipher enables glycan database-independent peptide matching and in-depth characterization of site-specific N-glycosylation. *Nat Commun*. 2022; 13.
100. Lu L, Riley NM, Shortreed MR, Bertozzi CR, Smith LM. O-Pair Search with MetaMorpheus for O-glycopeptide characterization. *Nat Methods*. 2020; 17: 1133–8.
101. Liu MQ, Zeng WF, Fang P, et al. pGlyco 2.0 enables precision N-glycoproteomics with comprehensive quality control and one-step mass spectrometry for intact glycopeptide identification. *Nat Commun*. 2017; 8: 1–14.
102. Shu Q, Li M, Shu L, et al. Large-scale identification of n-linked intact glycopeptides in human serum using HILIC enrichment and spectral library search. *Mol Cell Prot*. 2020; 19: 672–89.
103. Reinhold VN, Reinhold BB, Costello CE. Carbohydrate Molecular Weight Profiling, Sequence, Linkage, and Branching Data: ES-MS and CID. *Anal Chem*. 1995; 67: 1772–84.
104. Ruhaak LR, Xu G, Li Q, Goonatilake E, Lebrilla CB. Mass Spectrometry Approaches to Glycomic and Glycoproteomic Analyses. *Chem Rev*. 2018; 118: 7886–930.
105. Jensen PH, Karlsson NG, Kolarich D, Packer NH. Structural analysis of N- and O-glycans released from glycoproteins. *Nat Protoc*. 2012; 7: 1299–310.
106. Tiemeyer M, Aoki K, Paulson J, et al. GlyTouCan: an accessible glycan structure repository. *Glycobiology*. 2017; 27: 915–9.
107. Sun S, Shah P, Eshghi ST, et al. Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides. *Nat Biotechnol*. 2016; 34: 84–8.
108. Chau TH, Chernykh A, Ugonotti J, Parker BL, Kawahara R, Thaysen-Andersen M. Glycomics-Assisted Glycoproteomics Enables Deep and Unbiased N-Glycoproteome Profiling of Complex Biological Specimens. *Methods Mol Biol*. 2023; 2628: 235–63.
109. Zhang Z, Ollmann IR, Ye XS, Wischnat R, Baasov T, Wong CH. Programmable One-Pot Oligosaccharide Synthesis. *J Am Chem Soc*. 1999; 121: 734–53.
110. Sears P, Wong CH. Toward Automated Synthesis of Oligosaccharides and Glycoproteins. *Science*. 2001; 291: 2344–50.
111. Li C, Wang LX. Chemoenzymatic Methods for the Synthesis of Glycoproteins. *Chem Rev*. 2018; 118: 8359–413.
112. Li T, Liu L, Wei N, et al. An automated platform for the enzyme-mediated assembly of complex oligosaccharides. *Nat Chem*. 2019; 11: 229–36.
113. Liu L, Prudden AR, Capicciotti CJ, et al. Streamlining the chemoenzymatic synthesis of complex N-glycans by a stop and go strategy. *Nat Chem*. 2018; 11: 161–9.
114. Mehta AY, Kumar R, Veeriah H, et al. Parallel Glyco-SPOT Synthesis of Glycopeptide Libraries. *Cell Chem Biol*. 2020; 27: 1207–1219.e9.
115. Pett C, Nasir W, Sihlbom C, et al. Effective Assignment of $\alpha 2,3/\alpha 2,6$ -Sialic Acid Isomers by LC-MS/MS-Based Glycoproteomics. *Angew Chem Int Ed Engl*. 2018; 57: 1152–5.
116. Maliepaard JCL, Mirjam J, Damen A, Boons G-JPH, Reiding KR. Glycoproteomics-compatible MS/MS-based quantification of glycopeptide isomers. *bioRxiv*. 2023; 2023.01.31.526390.
117. Halim A, Westerlind U, Pett C, et al. Assignment of saccharide identities through analysis of oxonium ion fragmentation profiles in LC-MS/MS of glycopeptides. *J Proteome Res*. 2014; 13: 6024–32.
118. Gessulat S, Schmidt T, Zolg DP, et al. Prosit: proteome-wide prediction of peptide tandem mass spectra by deep learning. *Nat Methods*. 2019; 16: 509–18.
119. Wollscheid B, Bausch-Fluck D, Henderson C, et al. Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. *Nat Biotechnol*. 2009; 27: 378–86.
120. Bausch-Fluck D, Hofmann A, Bock T, et al. A Mass Spectrometric-Derived Cell Surface Protein Atlas. *PLoS One*. 2015; 10: e0121314.
121. Bausch-Fluck D, Goldmann U, Müller S, et al. The *in silico* human surfaceome. *Proc Natl Acad Sci USA*. 2018; 115: E10988–97.
122. Waas M, Snarrenberg ST, Littrell J, et al. SurfaceGenie: a web-based application for prioritizing cell-type-specific marker candidates. *Bioinformatics*. 2020; 36: 3447–56.
123. Waas M, Littrell J, Gundry RL. CIRFESS: An Interactive Resource for Querying the Set of Theoretically Detectable Peptides for Cell Surface and Extracellular Enrichment Proteomic Studies. *J Am Soc Mass Spectrom*. 2020; 31: 1389–97.
124. Berg Luecke L, Waas M, Littrell J, et al. Surfaceome mapping of primary human heart cells with CellSurfer uncovers cardiomyocyte surface protein LSMEM2 and proteome dynamics in failing hearts. *Nat Cardiovasc Res*. 2023; 2: 76–95.
125. Nilsson J, Rüetschi U, Halim A, et al. Enrichment of glycopeptides for glycan structure and attachment site identification. *Nat Methods*. 2009; 6: 809–11.
126. Keppeler OT, Horstkorte R, Pawlita M, Schmidt C, Reutter W. Biochemical engineering of the N-acyl side chain of sialic acid: biological implications. *Glycobiology*. 2001; 11.
127. Tornøe CW, Christensen C, Meldal M. Peptidotriazoles on solid phase: [1,2,3]-Triazoles by regioselective copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. *J Org Chem*. 2002; 67: 3057–64.
128. Rostovtsev V V, Green LG, Fokin V V, Sharpless KB. A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes. *Angew Chem Int Ed Engl*. 2002; 41: 2596–9.
129. Agard NJ, Prescher JA, Bertozzi CR. A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. *J Am Chem Soc*. 2004; 126: 15046–7.
130. Laughlin ST, Baskin JM, Amacher SL, Bertozzi CR. *In vivo* imaging of membrane-associated glycans in developing zebrafish. *Science*. 2008; 320: 664–7.
131. Sletten EM, Bertozzi CR. Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality. *Angew Chem Int Ed Engl*. 2009; 48: 6974–98.
132. Palaniappan KK, Bertozzi CR. Chemical Glycoproteomics. *Chem Rev*. 2016; 116: 14277–306.
133. Sun T, Yu SH, Zhao P, et al. One-Step Selective Exoenzymatic Labeling (SEEL) Strategy for the Biotinylation and Identification of Glycoproteins of Living Cells. *J Am Chem Soc*. 2016; 138: 11575–82.
134. Chen W, Smeekens JM, Wu R. Systematic and site-specific analysis of N-sialoglycosylated proteins on the cell surface by integrating click chemistry and MS-based proteomics. *Chem Sci*. 2015; 6: 4681–9.
135. Xiao H, Tang GX, Wu R. Site-Specific Quantification of Surface N-Glycoproteins in Statin-Treated Liver Cells. *Anal Chem*. 2016; 88: 3324–32.
136. Suttapitugsakul S, Tong M, Wu R. Time-Resolved and Comprehensive Analysis of Surface Glycoproteins Reveals Distinct Responses of Monocytes and Macrophages to Bacterial Infection. *Angew Chem Int Ed Engl*. 2021; 60: 11494–503.
137. Woo CM, Iavarone AT, Spiciarich DR, Palaniappan KK, Bertozzi CR. Isotope-targeted glycoproteomics (IsoTaG): a mass-independent platform for intact N- and O-glycopeptide discovery and analysis. *Nat Methods*. 2015; 12: 561–7.
138. Woo CM, Felix A, Byrd WE, et al. Development of IsoTaG, a Chemical Glycoproteomics Technique for Profiling Intact N- and O-Glycopeptides from Whole Cell Proteomes. *J Proteome Res*. 2017; 16: 1706–18.

139. Woo CM, Lund PJ, Huang AC, Davis MM, Bertozzi CR, Pitteri SJ. Mapping and quantification of over 2000 O-linked glycopeptides in activated human T cells with isotope-targeted glycoproteomics (Isotag). *Mol Cell Prot.* 2018; 17: 764–75.
140. Leung KK, Wilson GM, Kirkemo LL, Riley NM, Coon JJ, Wells JA. Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes. *Proc Natl Acad Sci USA.* 2020; 117: 7764–75.
141. Berg Luecke L, Waas M, Littrell J, et al. Surfaceome mapping of primary human heart cells with CellSurfer uncovers cardiomyocyte surface protein LSMEM2 and proteome dynamics in failing hearts. *Nat Cardiovasc Res.* 2023; 2: 76–95.
142. Ferguson ID, Patiño-Escobar B, Tuomivaara ST, et al. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. *Nature Commun.* 2022; 13: 1–17.
143. Park DD, Xu G, Wong M, et al. Membrane glycomics reveal heterogeneity and quantitative distribution of cell surface sialylation. *Chem Sci.* 2018; 9: 6271–85.
144. Li Q, Xie Y, Wong M, Barboza M, Lebrilla CB. Comprehensive structural glycomic characterization of the glycocalyxes of cells and tissues. *Nat Protoc.* 2020; 15: 2668–704.
145. Nayak S, Zhao Y, Mao Y, Li N. System-Wide Quantitative N-Glycoproteomic Analysis from K562 Cells and Mouse Liver Tissues. *J Proteome Res.* 2021; 20: 5196–202.
146. Chen YJ, Yen TC, Lin YH, Chen YL, Khoo KH, Chen YJ. ZIC-cHILIC-Based StageTip for Simultaneous Glycopeptide Enrichment and Fractionation toward Large-Scale N-Sialoglycoproteomics. *Anal Chem.* 2021; 93: 15931–40.
147. Rabinovich GA, Toscano MA. Turning ‘sweet’ on immunity: galectin–glycan interactions in immune tolerance and inflammation. *Nat Rev Immunol.* 2009; 9: 338–52.
148. Rodríguez E, Schetters STT, Van Kooyk Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. *Nat Rev Immunol.* 2018; 18: 204–11.
149. Duan S, Paulson JC. Siglecs as Immune Cell Checkpoints in Disease. *Annu Rev Immunol.* 2020; 38: 365–95.
150. Li Q, Xie Y, Xu G, Lebrilla CB. Identification of potential sialic acid binding proteins on cell membranes by proximity chemical labeling. *Chem Sci.* 2019; 10: 6199–209.
151. Joeh E, O’Leary T, Li W, et al. Mapping glycan-mediated galectin-3 interactions by live cell proximity labeling. *Proc Natl Acad Sci USA.* 2020; 117: 27329–38.
152. Cagnoni AJ, Laura Giribaldi M, Blidner AG, et al. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8 + regulatory T cells. *Proc Natl Acad Sci USA.* 2021; 118:e2102950118
153. Wisnovsky S, Möckl L, Malaker SA, et al. Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7. *Proc Natl Acad Sci USA.* 2021; 118: e2015024118.
154. Flynn RA, Pedram K, Malaker SA, et al. Small RNAs are modified with N-glycans and displayed on the surface of living cells. *Cell.* 2021; 184: 3109–3124.e22.
155. Yang R, Sun L, Li CF, et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. *Nat Commun.* 2021; 12: 1–17.
156. Pan J, Hu Y, Sun S, et al. Glycoproteomics-based signatures for tumor subtyping and clinical outcome prediction of high-grade serous ovarian cancer. *Nat Commun.* 2020; 11: 1–13.
157. Hasegawa K, Ikeda S, Yaga M, et al. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. *Sci Transl Med.* 2022; 14.
158. Mondal N, Silva M, Castano AP, Maus M v., Sackstein R. Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding. *J Biol Chem.* 2019; 294: 18465–74.
159. Greco B, Malacarne V, DeGirardi F, et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. *Sci Transl Med.* 2022; 14.
160. Posey AD, Schwab RD, Boesteanu AC, et al. Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. *Immunity.* 2016; 44: 1444–54.
161. Heard A, Landmann JH, Hansen AR, et al. Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. *Nature.* 2022; 13: 1–11.
162. Liu K, Tan S, Jin W, et al. N-glycosylation of PD-1 promotes binding of camrelizumab. *EMBO Rep.* 2020; 21.
163. Lu D, Xu Z, Zhang D, et al. PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy. *Front Immunol.* 2022; 13.
164. Desai K, Mitchell A, Shah A, et al. Use of glycoproteome profiles to detect advanced adenomas and colorectal cancer. *J Clin Oncol.* 2023; 41: 69–69.
165. Lin S, Zhou S, Yuan T. The “sugar-coated bullets” of cancer: Tumor-derived exosome surface glycosylation from basic knowledge to applications. *Clin Transl Med.* 2020; 10: e204.
166. Malaker SA, Quanicco J, Raffo-Romero A, et al. On-tissue spatially resolved glycoproteomics guided by N-glycan imaging reveal global dysregulation of canine glioma glycoproteomic landscape. *Cell Chem Biol.* 2022; 29: 30–42.e4.